Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION (CVS)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

CVS Health : Revenue Rises as It Pursues Aetna

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/06/2017 | 02:11pm CEST
By Cara Lombardo 

Stronger pharmacy sales boosted CVS Health Corp.'s revenue in its latest quarter as the drugstore chain weighs a purchase of health insurer Aetna Inc., a move that would bolster its prescription business.

CVS's third-quarter revenue rose 3.5% to $46.2 billion, matching what analysts polled by Thomson Reuters expected.

The Wall Street Journal reported last month that the drugstore giant is in talks to buy Aetna for $66 billion, according to people familiar with the matter, following a six-month hunt for a deal partner. The move would strengthen CVS's position in negotiations with drugmakers, and analysts are likely to question company executives about the potential tie-up on a Monday earnings call.

People familiar with the discussions have said it could take until the end of the year to solidify a deal, if it happens.

In its latest quarter, sales in CVS's pharmacy-services segment increased 8.1% to $32.9 billion, driven by growth in pharmacy network claims and specialty pharmacy volume. Retail segment sales, meanwhile, slipped 2.7% to $19.6 billion, hurt by falling same-store sales.

The company also recorded $55 million in expenses related to the recent string of hurricanes, with most of it impacting the retail segment.

Overall for the quarter, CVS reported a profit of $1.3 billion, or $1.26 a share, compared with $1.5 billion, or $1.43 a share, a year ago.

Excluding one-time items, the Woonsocket, R.I.-based company earned $1.50 a share, compared with $1.64 a year ago. Analysts had expected adjusted earnings per share of $1.48 on net income of $1.5 billion.

The company also narrowed its full-year earnings guidance and raised the midpoint. It now expects adjusted earnings of $5.87 to $5.91. It previously guided a range of $5.83 to $5.93.

CVS shares, down 12% this year, rose less than 1% premarket on low volume.

Write to Cara Lombardo at cara.lombardo@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
AETNA -0.09% 201.38 Delayed Quote.10.28%
CVS HEALTH CORPORATION 0.27% 74.7573 Delayed Quote.2.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
10:37aJustice Department Requires CVS and Aetna to Divest Aetnas Medicare Individua..
AQ
10/18CVS PHARMACY : Completes Statewide Rollout of Time Delay Safes in Ohio Stores
PR
10/16CVS HEALTH : to Embark on Pilot Program to Combat Diabetes in Medically Underser..
PR
10/16CVS PHARMACY : Completes Rollout of Time Delay Safes in All of Its Maryland Phar..
PR
10/16CVS PHARMACY : Completes Rollout of Time Delay Safes in All Washington, DC Pharm..
PR
10/16CVS HEALTH : Appoints New CFO, Directors Following Aetna Deal
AQ
10/15CVS HEALTH : Encourages Consumers to Safely Dispose of Prescription Drugs Ahead ..
PR
10/12CVS HEALTH : AllazoHealth Hires Former CVS Executive as Growth Accelerates
AQ
10/11CVS Health Closes Down 7.26%, Largest Percent Decrease Since Nov 2016 -- Data..
DJ
10/11CVS and Bank of America fall while Delta Air Lines climbs
AQ
More news
News from SeekingAlpha
08:45aRite Aid - Vote 'Em Out On October 30th 
07:46aNew York threatens to block CVS-Aetna tie-up - NY Post 
10/182018 Third Quarter Review - Buying Dividend Growth Stocks Without Looking 
10/18GW Pharma Pipeline Will Add To Bottom Line And Stock Price 
10/18Connecticut Insurance Commish backs CVS-Aetna tie-up 
Financials ($)
Sales 2018 189 B
EBIT 2018 10 058 M
Net income 2018 1 476 M
Debt 2018 20 199 M
Yield 2018 2,79%
P/E ratio 2018 49,15
P/E ratio 2019 11,05
EV / Sales 2018 0,51x
EV / Sales 2019 0,48x
Capitalization 75 876 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 88,7 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Controller, Chief Financial & Accounting Officer
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors